Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Imugene Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Imugene kazanç ve gelirin sırasıyla yıllık 57.2% ve 56.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 57.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -41% olacağı tahmin edilmektedir.

Anahtar bilgiler

57.2%

Kazanç büyüme oranı

57.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	15.0%
Gelir büyüme oranı	56.8%
Gelecekteki özkaynak getirisi	-41.0%
Analist kapsamı	Low
Son güncelleme	25 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24

Kazanç ve Gelir Büyüme Tahminleri

ASX:IMU - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2027	317	51	-37	-37	1
6/30/2026	44	-88	-89	-89	2
6/30/2025	N/A	-120	-104	-104	2
6/30/2024	5	-150	-111	-102	N/A
3/31/2024	10	-119	-92	-81	N/A
12/31/2023	15	-89	-73	-61	N/A
9/30/2023	13	-64	-52	-46	N/A
6/30/2023	12	-38	-31	-31	N/A
3/31/2023	12	-39	-37	-37	N/A
12/31/2022	12	-40	-42	-42	N/A
9/30/2022	13	-39	-36	-36	N/A
6/30/2022	13	-38	-31	-31	N/A
3/31/2022	11	-33	-27	-25	N/A
12/31/2021	8	-27	-24	-20	N/A
9/30/2021	8	-23	-21	-16	N/A
6/30/2021	7	-18	-19	-13	N/A
3/31/2021	7	-15	-16	-12	N/A
12/31/2020	6	-12	-12	-11	N/A
9/30/2020	5	-11	-12	-11	N/A
6/30/2020	4	-11	-12	-10	N/A
3/31/2020	5	-10	-11	-10	N/A
12/31/2019	5	-9	-10	-9	N/A
9/30/2019	5	-8	-9	-8	N/A
6/30/2019	4	-8	-8	-8	N/A
3/31/2019	3	-7	-7	-7	N/A
12/31/2018	3	-6	-7	-6	N/A
9/30/2018	2	-5	-6	-5	N/A
6/30/2018	2	-4	-5	-5	N/A
3/31/2018	1	-3	N/A	-4	N/A
12/31/2017	1	-3	N/A	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-3	N/A	-3	N/A
12/31/2016	2	-3	N/A	-3	N/A
9/30/2016	2	-3	N/A	-3	N/A
6/30/2016	2	-3	N/A	-3	N/A
3/31/2016	1	-3	N/A	-2	N/A
12/31/2015	1	-2	N/A	-2	N/A
9/30/2015	1	-2	N/A	-2	N/A
6/30/2015	1	-2	N/A	-2	N/A
3/31/2015	1	-2	N/A	-2	N/A
12/31/2014	1	-2	N/A	-2	N/A
9/30/2014	1	-2	N/A	-1	N/A
6/30/2014	1	-2	N/A	-1	N/A
3/31/2014	0	-2	N/A	-1	N/A
12/31/2013	0	-2	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IMU önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.4% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: IMU önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: IMU önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: IMU gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: IMU gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: IMU 3 yıl içinde kârsız olması bekleniyor.

Imugene Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast to breakeven in 2027

Price target decreased by 8.2% to AU$0.34

No longer forecast to breakeven

Price target decreased by 14% to AU$0.42

Price target decreased by 14% to AU$0.42

Forecast to breakeven in 2026

Recent updates

Imugene Limited Announces Promising Results from its Phase 1b Clinical Trial with Azer-Cel

New minor risk - Financial position

Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

Forecast to breakeven in 2027

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

Price target decreased by 8.2% to AU$0.34

New minor risk - Share price stability

Imugene Limited, Annual General Meeting, Nov 30, 2023

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 14% to AU$0.42

Less than half of directors are independent

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Price target decreased by 14% to AU$0.42

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Imugene Appoints Dr Weitzman Interim Chief Medical Officer

Forecast to breakeven in 2026

Imugene Limited Announces Board Changes

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Price target decreased by 9.8% to AU$0.46

Imugene Limited Announces VAXINIA Trial Advances to Combination Cohort 1 & Monotherapy Cohort 3

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Receives Vaxinia Ethics Approval in Australia

Imugene Limited Presents New and First CHECKvacc Data At the 2022 San Antonio Breast Cancer Symposium

Imugene Limited Announces First Patient Dosed in VAXINIA Intravenous Cohort 2

Insufficient new directors

Price target decreased to AU$0.52

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Independent Non-Executive Director exercised options to buy AU$3.2m worth of stock.

Imugene Limited Announces That First Patient Dosed in VAXINIA Intratumoral Cohort 2

Imugene Limited, Annual General Meeting, Nov 17, 2022

Price target decreased to AU$0.51

Imugene Limited Announces First patient IV dosed in VAXINIA Phase 1 clinical trial

Imugene Limited Announces That Australian Government's Office of the Gene Technology Regulator (Ogtr) Has Granted Imugene the Dir Licence Required to Expand Its Vaxinia Phase 1 Clinical Trial Within Australia

Consensus forecasts updated

Price target decreased to AU$0.52

Imugene Limited Doses First Patient in nextHERIZON Phase 2 Trial

Imugene Appoints Jakob Dupont as Non- Executive Director

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Announces First Cohort 3 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Appoints Mike Tonroe as Chief Financial Officer, Effective from September 2022

Imugene Limited Announces Appointment of Dr. Sharon Yavrom as Executive Director, Clinical Scientist

Imugene Limited Announces Final HER-Vaxx Phase 2 Trial Overall Survival Results

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$1.5m worth of stock.

Imugene Limited Announces Board Changes

City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors

Imugene Limited Receives Ethics Approval to Start Phase 2 nextHERIZON Clinical Trial of Cancer Immunotherapy HER-VAXX

Imugene Limited Announces First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

Consensus forecasts updated

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Imugene Limited Announces Appointment of Steven Cha as Chief Medical Officer and Member of the Executive Management Team

Imugene Limited Receives Notice of Grant from the European Patent Office for Patent Application Number

Imugene Completes Phase 1a Monotherapy Dose Escalation of Immunotherapy PD1-Vaxx

Executive Chairman recently sold AU$37m worth of stock

Imugene Limited Receives US Food and Drug Administration (FDA) Investigational New Drug (IND) Approval to Initiate A Phase I Clinical Trial of its Oncolytic Virotherapy Candidate, Vaxinia (CF33-hNIS, HOV2)

Imugene Limited Provides Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc

Insider recently sold AU$1.4m worth of stock

Imugene Limited Provides Phase 1 Clinical Trial Update of Its Immunotherapy Pd1-Vaxx

Imugene Presents HER-Vaxx Update at ESMO World GI Congress

Imugene Limited Announces FDA IND Approval of New Oncolytic Virotherapy Checkvacc Virotherapy Checkvacc

CEO, MD & Executive Director exercised options and sold AU$1.6m worth of stock